063160.KS
CKD Bio Corp.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 13,600.00
−0.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 158.1B | 160.1B | 171.8B | 160.4B | 156.0B |
| Cost of Revenue | 144.5B | 134.0B | 135.8B | 155.3B | 139.3B |
| Gross Profit | 13.6B | 26.1B | 35.9B | 5.0B | 16.8B |
| Operating Expenses | |||||
| R&D Expense | (1.9B) | 3.4B | 13.5B | 12.7B | 15.4B |
| SG&A Expense | 5.4B | 6.8B | 5.5B | 12.5B | 9.1B |
| General & Admin Expense | 3.6B | 4.0B | 2.1B | 3.3B | 5.8B |
| Selling & Marketing Expense | 1.8B | 2.8B | 3.4B | 3.3B | 3.4B |
| Other Expenses | 11.7B | 12.3B | 6.0B | 6.6B | 7.0B |
| Total Operating Expenses | 22.0B | 22.5B | 25.0B | 25.2B | 31.6B |
| Cost and Expenses | 166.2B | 156.5B | 160.8B | 180.5B | 170.9B |
| Operating Income (EBIT) | (8.1B) | 3.6B | 11.0B | (20.2B) | (14.8B) |
| Non-Operating | |||||
| Interest Income | 26.9M | 31.3M | 99.6M | 374.3M | 48.1M |
| Interest Expense | 5.6B | 5.6B | 5.3B | 5.0B | 2.9B |
| Net Interest Income | (5.6B) | (5.6B) | (5.2B) | (4.6B) | (2.9B) |
| Other Non-Op Income/Expense | (2.9B) | (6.6B) | (1.7B) | (4.0B) | (3.8B) |
| Non-Operating Income (excl Interest) | (1.0B) | — | (3.5B) | (944.5M) | 841.2M |
| EBT (Pre-Tax Income) | (10.9B) | (3.0B) | 9.2B | (24.2B) | (18.6B) |
| Income Tax Expense | (189.6M) | (78.3M) | 515.3M | (4.1M) | (1.9B) |
| Bottom Line | |||||
| Net Income | (10.7B) | (2.9B) | 8.7B | (24.2B) | (16.7B) |
| Earnings from Cont. Ops | (10.7B) | (2.9B) | 8.7B | (24.2B) | (16.7B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.7B) | (2.9B) | 8.7B | (24.2B) | (16.7B) |
| Per Share | |||||
| Basic EPS | (₩1,958) | (₩526) | ₩1,586 | (₩4,410) | (₩3,045) |
| Diluted EPS | (₩1,958) | (₩526) | ₩1,586 | (₩4,410) | (₩3,045) |
| Revenue Per Share | ₩28,822 | ₩29,162 | ₩31,308 | ₩29,230 | ₩28,444 |
| Shares | |||||
| Basic Shares Outstanding | 5.5M | 5.5M | 5.5M | 5.5M | 5.5M |
| Diluted Shares Outstanding | 5.5M | 5.5M | 5.5M | 5.5M | 5.5M |
| Profitability Metrics | |||||
| EBITDA | 8.5B | 19.3B | 31.2B | (1.6B) | 2.3B |
| D&A | 15.9B | 15.7B | 16.7B | 17.6B | 17.9B |
| EBIT | (7.4B) | 3.6B | 14.5B | (19.2B) | (15.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026